Dermata Therapeutics, initially focused on prescription acne treatment XYNGARI, achieved positive Phase 3 results but pivoted in late 2025 to developing OTC skincare leveraging its unique Bioneedle technology. This strategic shift aims to reduce regulatory hurdles and accelerate time to market with a dual channel distribution model. The company faces challenges inherent in regulatory compliance, competition, and manufacturing scale-up amid ongoing net losses. Monitoring consumer adoption of upcoming OTC product launches in mid-2026 will be crucial.